BRIACELL THERAPEUTICS CORP. Assets, Fair Value Disclosure
BRIACELL THERAPEUTICS CORP. (BCTX) had Assets, Fair Value Disclosure of $22.80 million as of 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Notes › Fair Value, Net Asset (Liability)
us-gaap:AssetsFairValueDisclosure · last filed 2026-06-09
- 2026-04-30: Assets, Fair Value Disclosure $22.80M.
- 2026-01-31: Assets, Fair Value Disclosure $29.90M.
- 2025-10-31: Assets, Fair Value Disclosure $10.18M.
- 2025-07-31: Assets, Fair Value Disclosure $17.87M.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2026-04-30 | $22.80M 10-Q · filed 2026-06-09 |
| 2026-01-31 | $29.90M 10-Q · filed 2026-03-10 |
| 2025-10-31 | $10.18M 10-Q · filed 2025-12-11 |
| 2025-07-31 | $17.87M 10-Q · filed 2026-06-09 |
| 2025-04-30 | $12.46M 10-Q · filed 2025-06-16 |
| 2025-01-31 | $5.01M 10-Q · filed 2025-03-12 |
| 2024-10-31 | $5.79M 10-Q · filed 2024-12-16 |
| 2024-07-31 | $862.09K 10-K · filed 2025-10-16 |
| 2024-04-30 | $935.69K 10-Q · filed 2024-06-14 |
| 2024-01-31 | $6.24M 10-Q · filed 2024-03-18 |
| 2023-10-31 | $13.65M 10-Q · filed 2023-12-14 |
| 2023-07-31 | $21.25M 10-K · filed 2024-10-29 |
| 2023-04-30 | $28.17M 10-Q · filed 2023-06-14 |
| 2023-01-31 | $33.50M 10-Q · filed 2023-03-16 |
| 2022-10-31 | $37.45M 10-Q · filed 2022-12-14 |
| 2022-07-31 | $41.04M 10-K · filed 2023-10-25 |
| 2021-07-31 | $57.27M 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |